Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.
Where this comes from
- Record sourced from PubMed, PMID 35396200.
- Also identified by DOI 10.1016/j.pcd.2022.03.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV risk or established ASCVD, GLP-1RAs significantly reduced MACE while SGLT-2is resulted in a non-significant reduction.
Medical subject headings
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors